Search

everythinglearnresearchcommunity

for

Search:↓

Patients prioritize quality of life, overall survival, and progression-free survival in treatment decisions for advanced breast cancer.

The number of advanced breast cancer cases in women under 40 has increased, but the overall numbers are still low.

Dalpiciclib is the safest and most satisfying CDK4/6 inhibitor for advanced breast cancer patients in China.

Fulvestrant is a well-tolerated new treatment for advanced breast cancer that may delay chemotherapy.

Patients with advanced breast cancer and high hormone receptor levels who had surgery for ovarian/pelvic metastases lived longer, especially if they had high estrogen receptor levels.

Capivasertib improves survival in certain breast cancer cases but requires careful management of side effects.

Patients with HR+/HER2- advanced breast cancer commonly experience fatigue, hair loss, and pain, which significantly affect daily activities.

CDK4/6 inhibitors affect safety and quality of life differently, requiring careful use.

Patients with advanced breast cancer prioritize quality of life, overall survival, and progression-free survival in treatment decisions.

The combination of high-dose toremifene and capecitabine was effective for advanced recurrent breast cancer.

Trastuzumab deruxtecan is effective for advanced breast cancer but has side effects like nausea and fatigue.

Formestane is a preferred second-line treatment for advanced breast cancer in postmenopausal women because it's effective and has fewer side effects.

BI 2536 had limited effectiveness against several advanced cancers and caused significant side effects.

Cinobufacin with chemotherapy improves treatment response and quality of life in advanced breast cancer patients while reducing some side effects.

Palbociclib generally maintains or improves quality of life in advanced breast cancer patients.

Quality of life, overall survival, and progression-free survival should be equally prioritized in advanced breast cancer treatment decisions.

The combination of gemcitabine and vinorelbine is effective and safe for treating elderly patients with advanced breast cancer previously treated with anthracyclines and taxanes.

CDK4/6 inhibitors have improved treatment outcomes for certain advanced breast cancer patients.

Eribulin-based chemotherapy is more effective and has fewer side effects for advanced triple-negative breast cancer.

Targeting androgen receptors shows promise for treating triple-negative breast cancer, but more research is needed.

Low Vitamin D receptor levels in breast cancer are linked to worse outcomes and more bone metastases, and could be a marker for prognosis.

Sacituzumab govitecan improves quality of life and extends life for breast cancer patients compared to standard chemotherapy.

More research is needed to understand chemotherapy-induced hair loss and its phases.

Early detection and multidisciplinary management of skin and mouth side effects from breast cancer treatments improve patient outcomes.

Electric pulse treatments for breast cancer show promise in being safer and more effective, with fewer side effects.

Talazoparib is more effective than standard chemotherapy for advanced breast cancer with BRCA mutations.

Sacituzumab govitecan improves quality of life and symptoms in breast cancer patients, except for causing more diarrhea.

New methods to make oxasteroids show promise for medical treatments like osteoporosis and breast cancer.

Exemestane is effective and safe for treating certain breast cancers, with mild side effects, but needs more research on long-term effects.

Early treatment is important for better hair regrowth in elderly women with hair loss.